Resolute Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Resolute Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-338	Closed	-$22K	–	75
2022 Q3	$22K	Hold	338	–	–	﹤0.01%	97
2022 Q2	$21K	Hold	338	–	–	﹤0.01%	92
2022 Q1	$21K	Hold	338	–	–	﹤0.01%	106
2021 Q4	$26K	Hold	338	–	–	﹤0.01%	112
2021 Q3	$38K	Hold	338	–	–	0.01%	144
2021 Q2	$55K	Hold	338	–	–	0.01%	75
2021 Q1	$41K	Buy	+338	New	+$51K	0.01%	86

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Resolute Advisors's CRSP Position: Q4 2022 in Review

Resolute Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 338 shares — an estimated $22K sold.

Resolute Advisors first reported a position in CRSP in Q1 2021 and held it in 7 quarters. The position peaked at $55K in Q2 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Resolute Advisors reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
Resolute Advisors sold 338 CRISPR Therapeutics shares in Q4 2022, an estimated $22K.
Resolute Advisors first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 7 quarters.
Resolute Advisors's CRISPR Therapeutics position peaked at $55K in Q2 2021.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Resolute Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.